Videos
Press Releases
2 Feb 2021
PRESS RELEASE: EORTC 1945 OligoRARE trial in oligometastatic rare cancers receives support by Anticancer Fund & Rising Tide Foundation
20 Jan 2021
PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
19 Sep 2020
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
16 Jul 2020
PRESS RELEASE: Advocacy Organizations and Professional Societies from Across the Globe Unite on Brain Tumour Patients’ Charter of Rights
Latest Newsletters
News
31 Jan 2023
First international recommendations on the use of item libraries for patient-reported outcome measurement
30 Jan 2023
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
19 Dec 2022
Completion of Patient Recruitment for International TIGER Study
12 Dec 2022
Brain Tumour Group,Breast Cancer Group,Head and Neck Cancer Group,Lung Cancer Group,News,Radiation Oncology Group
EORTC, CTI, and IRROG collaboration opens new opportunities in Ireland
2 Dec 2022
EORTC, SPO and AICIB establish a partnership to promote cancer clinical research in Portugal
29 Nov 2022
Stakeholders’ consensus response to the proposed European Health Data Space
25 Nov 2022
Concepts assessed in the EORTC QLQ-C30 questionnaire are important and relevant for patients with cancer
17 Nov 2022
EORTC and KHCC sign first Middle Eastern collaboration agreement
10 Nov 2022
EORTC PhD fellow Emma Willems addresses how do leaders of international non-profit organizations deal with resource pressures caused by the COVID-19 pandemic
7 Oct 2022
EORTC: The Future of Cancer Therapy
